Detalhe da pesquisa
1.
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
Lancet
; 399(10319): 36-49, 2022 01 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34883053
2.
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Lancet
; 398(10303): 856-869, 2021 09 04.
Artigo
Inglês
| MEDLINE | ID: mdl-34370971
3.
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial.
J Infect
; 87(3): 230-241, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37331429
4.
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
J Infect
; 86(6): 574-583, 2023 06.
Artigo
Inglês
| MEDLINE | ID: mdl-37028454
5.
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
Lancet Respir Med
; 10(11): 1049-1060, 2022 11.
Artigo
Inglês
| MEDLINE | ID: mdl-35690076